M&T Bank
AST

M&T Bank’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

M&T Bank’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,028
Closed -$39K – 1918
2015
Q3 		$39K Buy
+10,028
New +$46.1K ﹤0.01% 1702

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

M&T Bank's AST Position: Q4 2015 in Review

M&T Bank sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2015, closing a stake of 10,028 shares — an estimated $39K sold.

M&T Bank first reported a position in AST in Q3 2015 and held it in 1 quarter. The position peaked at $39K in Q3 2015. 56 funds tracked by Wall St. Rank hold AST as of Q4 2015.

  • M&T Bank reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2015 after selling out during the quarter.
  • M&T Bank sold 10,028 Asterias Biotherapeutics Inc. Series A shares in Q4 2015, an estimated $39K.
  • M&T Bank first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2015 and held it in 1 quarter.
  • M&T Bank's Asterias Biotherapeutics Inc. Series A position peaked at $39K in Q3 2015.
  • 56 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2015.

Based on M&T Bank's 13F filing for Q4 2015, filed 12 Feb 2016.